Eisai (ESAIY) and Biogen Inc. (BIIB) announced that the humanized amyloid-beta monoclonal antibody Leqembi has been granted a marketing authorization by the Medicines and Healthcare products Regulatory Agency, or MHRA, in Great Britain. Lecanemab is indicated for the treatment of mild cognitive impairment and mild dementia due to Alzheimer’s disease in adult patients that are apolipoprotein E e4 heterozygotes or non-carriers. Lecanemab becomes the first treatment for early AD that targets an underlying cause of the disease, to be authorized in a country in Europe.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen Enhances Financial Flexibility with New Credit Facility
- Canaccord reiterates Buy rating on Clene following ‘intriguing’ new data
- Biogen price target lowered to $298 from $308 at Canaccord
- Biogen price target lowered to $251 from $277 at Mizuho
- Biogen price target lowered to $302 from $340 at Truist